📰 GPCR Weekly News

Hello Readers👋,

We are working on bringing your the latest GPCR News more frequently directly in your inbox and in the Ecosystem. Below is your Classified GPCR News at a glance for December 12 to December 18th, 2022.

GPCR Activation and Signaling

• Molecular Mechanisms of PTH/PTHrP class B GPCR Signaling and Pharmacological Implications.

GPCR Binders, Drugs, and more

• Persistent challenges in the development of an mGlu7 PAM in vivo tool compound: The discovery of VU6046980.

• Phenotypic screen identifies the natural product silymarin as a novel anti-inflammatory analgesic.

GPCRs in Neuroscience

• Photopharmacological manipulation of amygdala metabotropic glutamate receptor mGlu4 alleviates neuropathic pain.

• GRK5 Deficiency in the Hippocampus Leads to Cognitive Impairment via Abnormal Microglial Alterations.

GPCRs in Oncology and Immunology

• Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors.

Methods & Updates in GPCR Research

• 3,4-Bis(hydroxymethyl)hexane-1,6-diol-based Maltosides (HDMs) for Membrane-Protein Study: Importance of Detergent Rigidity-Flexibility Balance in Protein Stability.

• iORbase: a database for the prediction of the structures and functions of insect olfactory receptors.

GPCR Industry News

• Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board

• Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases

• Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders

• Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

• Chris Cargill, President and CEO, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference.

• Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical Trials for Treating Type 2 Diabetes and Obesity

• Special report 2022: Meet 20 women blazing trails in biopharma R&D

• ERNEST - 2022 Scientific Outputs

Call for GPCR Papers

• GPCRs: Signal Transduction. Deadline February 12, 2023

• Current Technologies To Understand G-Protein-Coupled Receptor Molecular Pharmacology. Deadline January 30, 2023.

GPCR Events, Meetings, and Webinars

• 2nd GPCR-Targeted Drug Discovery Summit | February 21-23, Boston.

• 2nd ERNEST Training School – February 20th to March 3rd.

• GEM2023 (14-17 March 2023).

• 8th and final ERNEST Meeting May 3-7, 2023 in Crete.

• The Illuminating the Understudied Druggable Proteome Conference. June 4-8,2023.

• 2023 Molecular Pharmacology (GRS) Seminar GRC. June 10 - 11.

• Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential. June 11-16, 2023.

• 19th World Congress of Basic & Clinical Pharmacology 2023. July 2 - 7.

Explore Dr. GPCR Ecosystem